01-December-2016 — CSL has today announced that it has progressed three new therapies into first-in-human studies in Australia. In keeping with the Company’s objective to expand its research and development pipeline and pursue a diverse portfolio, all three products are new generation, high-tech medicines based on targeted monoclonal antibody technologies. More.
16-November-2016 — At the AHA Scientific Sessions in New Orleans, Louisiana, CSL Behring announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy.
Other recent news:
09-November-2016 — CSL congratulates Professor Mark Kendall from the University of Queensland on being awarded the 2016 CSL Young Florey Medal. Professor Kendall was recognised for developing a new vaccine technology known as a ‘Nanopatch’. More.
11-October-2016 — Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease. More.
30-August-2016 — CSL today announced that the FDA has accepted for review CSL Behring’s BLA for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent HAE attacks. More.